Amgen (AMGN) –
-
Form DEFA14A AMGEN INC
-
Form DEF 14A AMGEN INC For: May 31
-
Wells Fargo Reiterates Overweight Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Lowered to $284 at UBS
-
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
-
Amgen (AMGN) PT Lowered to $336 at BMO Capital
-
Form ARS AMGEN INC For: Dec 31
-
Amgen (AMGN) PT Lowered to $271 at Morgan Stanley
-
Raymond James Resumes Amgen (AMGN) at Market Perform
-
Amgen (AMGN) PT Lowered to $331 at DZ Bank
-
Form 4 AMGEN INC For: Mar 18 Filed by: Santos Esteban
-
Form 4 AMGEN INC For: Mar 18 Filed by: REESE DAVID M
-
Form 4 AMGEN INC For: Mar 18 Filed by: Miller Derek
-
Form 4 AMGEN INC For: Mar 18 Filed by: Khosla Rachna
-
Form 4 AMGEN INC For: Mar 18 Filed by: Grygiel Nancy A.
-
Form 4 AMGEN INC For: Mar 18 Filed by: Griffith Peter H.
-
Form 4 AMGEN INC For: Mar 18 Filed by: Graham Jonathan P
-
Form 4 AMGEN INC For: Mar 18 Filed by: Gordon Murdo
-
Form 4 AMGEN INC For: Mar 18 Filed by: Bradway Robert A
-
Form 4 AMGEN INC For: Mar 18 Filed by: Busch Matthew C.
-
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
-
Form 4 AMGEN INC For: Mar 06 Filed by: Santos Esteban
-
Form 4 AMGEN INC For: Mar 06 Filed by: REESE DAVID M
-
Form 4 AMGEN INC For: Mar 06 Filed by: Miller Derek
-
Form 4 AMGEN INC For: Mar 06 Filed by: Khosla Rachna
-
Form 4 AMGEN INC For: Mar 06 Filed by: Grygiel Nancy A.
-
Form 4 AMGEN INC For: Mar 06 Filed by: Griffith Peter H.
-
Form 4 AMGEN INC For: Mar 06 Filed by: Graham Jonathan P
-
Form 4 AMGEN INC For: Mar 06 Filed by: Gordon Murdo
-
Form 4 AMGEN INC For: Mar 06 Filed by: Busch Matthew C.
-
Form 4 AMGEN INC For: Mar 06 Filed by: Bradway Robert A
-
Amgen (AMGN) Declares $2.25 Quarterly Dividend; 3.3% Yield
-
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
-
Goldman removes Apple stock from 'US Conviction List - Directors' Cut'
-
Goldman Makes New Monthly Adjustments to Directors Cut Names, 'inclusion on this list is not a stock rating'
-
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
-
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
-
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
-
Form 10-K AMGEN INC For: Dec 31
-
Form SC 13G/A AMGEN INC Filed by: VANGUARD GROUP INC
-
Form 4 AMGEN INC For: Feb 09 Filed by: Bradner James E.
-
Amgen (AMGN) PT Raised to $333 at DZ Bank
-
Amgen (AMGN) PT Raised to $322 at HSBC
-
AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
-
Midday movers: Ford, Fortinet rise; Snap slumps
-
Amgen (AMGN) PT Lowered to $278 at Morgan Stanley
-
Amgen (AMGN) PT Raised to $380 at Oppenheimer
-
Leerink Partners Downgrades Amgen (AMGN) to Market Perform, 'Awaiting Obesity Results'
-
Amgen (AMGN) PT Raised to $329 at RBC Capital
-
Amgen (AMGN) PT Raised to $215 at Baird
Back to AMGN Stock Lookup